Karyopharm Therapeutics (KPTI) Other Operating Expenses (2019 - 2025)

Karyopharm Therapeutics has reported Other Operating Expenses for 7 years, with the latest figure at $1.5 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses rose 11.5% year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2025 stood at $5.9 million (down 0.97% YoY), and the FY2025 full-year result was $5.9 million, down 0.97% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $1.5 million, down from $2.1 million in the prior quarter.
• The five-year high for Other Operating Expenses was $2.1 million in Q3 2025, with the low at -$73.8 million in Q1 2021.
• Historically, Other Operating Expenses has averaged -$2.5 million across 5 years, with a median of $1.3 million in 2024.
• Annual changes were most pronounced in 2021 — Other Operating Expenses sank 9106.96% — and 2022, when it jumped 151.75%.
• Karyopharm Therapeutics' Other Operating Expenses stood at $742000.0 in 2021, then jumped by 151.75% to $1.9 million in 2022, then retreated by 20.45% to $1.5 million in 2023, then fell by 10.43% to $1.3 million in 2024, then rose by 11.5% to $1.5 million in 2025.
• The last three Other Operating Expenses figures came in at $1.5 million (Q4 2025), $2.1 million (Q3 2025), and $1.1 million (Q2 2025), per Business Quant data.